Logo image of SCPH

SCPHARMACEUTICALS INC (SCPH) Stock Fundamental Analysis

NASDAQ:SCPH - US8106481059 - Common Stock

5.52 USD
-0.01 (-0.18%)
Last: 8/27/2025, 8:17:18 PM
5.5291 USD
+0.01 (+0.16%)
After Hours: 8/27/2025, 8:17:18 PM
Fundamental Rating

2

SCPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. SCPH may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SCPH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SCPH has reported negative net income.
In the past year SCPH has reported a negative cash flow from operations.
SCPH had negative earnings in each of the past 5 years.
In the past 5 years SCPH always reported negative operating cash flow.
SCPH Yearly Net Income VS EBIT VS OCF VS FCFSCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

SCPH's Return On Assets of -114.28% is on the low side compared to the rest of the industry. SCPH is outperformed by 77.72% of its industry peers.
Industry RankSector Rank
ROA -114.28%
ROE N/A
ROIC N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
SCPH Yearly ROA, ROE, ROICSCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

SCPH's Gross Margin of 68.46% is fine compared to the rest of the industry. SCPH outperforms 76.17% of its industry peers.
The Profit Margin and Operating Margin are not available for SCPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPH Yearly Profit, Operating, Gross MarginsSCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

SCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCPH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SCPH has been increased compared to 5 years ago.
Compared to 1 year ago, SCPH has a worse debt to assets ratio.
SCPH Yearly Shares OutstandingSCPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SCPH Yearly Total Debt VS Total AssetsSCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -6.56, we must say that SCPH is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.56, SCPH is doing worse than 63.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.56
ROIC/WACCN/A
WACC10.66%
SCPH Yearly LT Debt VS Equity VS FCFSCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

SCPH has a Current Ratio of 3.85. This indicates that SCPH is financially healthy and has no problem in meeting its short term obligations.
SCPH has a Current ratio of 3.85. This is in the better half of the industry: SCPH outperforms 63.73% of its industry peers.
A Quick Ratio of 3.14 indicates that SCPH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.14, SCPH is in line with its industry, outperforming 59.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.85
Quick Ratio 3.14
SCPH Yearly Current Assets VS Current LiabilitesSCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SCPH have decreased strongly by -16.03% in the last year.
SCPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 107.75%.
EPS 1Y (TTM)-16.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
Revenue 1Y (TTM)107.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%99.17%

3.2 Future

The Earnings Per Share is expected to grow by 24.37% on average over the next years. This is a very strong growth
SCPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 54.53% yearly.
EPS Next Y42.69%
EPS Next 2Y37.1%
EPS Next 3Y32.68%
EPS Next 5Y24.37%
Revenue Next Year105.36%
Revenue Next 2Y91.35%
Revenue Next 3Y74.69%
Revenue Next 5Y54.53%

3.3 Evolution

SCPH Yearly Revenue VS EstimatesSCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SCPH Yearly EPS VS EstimatesSCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPH Price Earnings VS Forward Price EarningsSCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPH Per share dataSCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as SCPH's earnings are expected to grow with 32.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.1%
EPS Next 3Y32.68%

More info and screens

0

5. Dividend

5.1 Amount

SCPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCPHARMACEUTICALS INC

NASDAQ:SCPH (8/27/2025, 8:17:18 PM)

After market: 5.5291 +0.01 (+0.16%)

5.52

-0.01 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners59.44%
Inst Owner Change0.97%
Ins Owners6.08%
Ins Owner Change0%
Market Cap294.22M
Analysts83.64
Price Target15.91 (188.22%)
Short Float %2.53%
Short Ratio3.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.79%
Min EPS beat(2)-21.73%
Max EPS beat(2)-11.86%
EPS beat(4)1
Avg EPS beat(4)-43.07%
Min EPS beat(4)-147.99%
Max EPS beat(4)9.3%
EPS beat(8)3
Avg EPS beat(8)-18.67%
EPS beat(12)7
Avg EPS beat(12)-7.96%
EPS beat(16)10
Avg EPS beat(16)-3.09%
Revenue beat(2)1
Avg Revenue beat(2)0.56%
Min Revenue beat(2)-0.92%
Max Revenue beat(2)2.03%
Revenue beat(4)1
Avg Revenue beat(4)-2.33%
Min Revenue beat(4)-9%
Max Revenue beat(4)2.03%
Revenue beat(8)4
Avg Revenue beat(8)0.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.86%
EPS NQ rev (1m)4.88%
EPS NQ rev (3m)-3.23%
EPS NY rev (1m)-2.15%
EPS NY rev (3m)-4.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.89
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.94
BVpS-0.4
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -114.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.46%
FCFM N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.85
Quick Ratio 3.14
Altman-Z -6.56
F-Score2
WACC10.66%
ROIC/WACCN/A
Cap/Depr(3y)23.53%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
EPS Next Y42.69%
EPS Next 2Y37.1%
EPS Next 3Y32.68%
EPS Next 5Y24.37%
Revenue 1Y (TTM)107.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%99.17%
Revenue Next Year105.36%
Revenue Next 2Y91.35%
Revenue Next 3Y74.69%
Revenue Next 5Y54.53%
EBIT growth 1Y-10.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.95%
OCF growth 3YN/A
OCF growth 5YN/A